ERBB2 and breast cancer: Notably, DESTINY-Breast05 (NCT04622319), a large phase III trial, is testing the efficacy of trastuzumab-deruxtecan (T-DXd) or T-DM1 in patients with HER2+ early BC without pCR after NAC.